Grossman HB - Search Results

1

Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.

Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y. Grossman HB, et al. JAMA. 2006 Jan 18;295(3):299-305. doi: 10.1001/jama.295.3.299. JAMA. 2006. PMID: 16418465

2

Detection of bladder cancer using a point-of-care proteomic assay.

Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y. Grossman HB, et al. JAMA. 2005 Feb 16;293(7):810-6. doi: 10.1001/jama.293.7.810. JAMA. 2005. PMID: 15713770

3

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.

Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Lokeshwar VB, et al. Among authors: grossman hb. Urology. 2005 Dec;66(6 Suppl 1):35-63. doi: 10.1016/j.urology.2005.08.064. Urology. 2005. PMID: 16399415

4

The use of urine-based biomarkers in bladder cancer.

Grossman HB, Blute ML, Dinney CP, Jones JS, Liou LS, Reuter VE, Soloway MS. Grossman HB, et al. Urology. 2006 Mar;67(3 Suppl 1):62-4. doi: 10.1016/j.urology.2006.01.036. Urology. 2006. PMID: 16530080 No abstract available.

5

Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.

Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, Kriegmair M, Karl A, Shen Y, Grossman HB. Stenzl A, et al. Among authors: grossman hb. J Urol. 2010 Nov;184(5):1907-13. doi: 10.1016/j.juro.2010.06.148. Epub 2010 Sep 17. J Urol. 2010. PMID: 20850152 Free PMC article. Clinical Trial.

6

Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy.

Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, Soloway MS, Karl A, Burger M. Grossman HB, et al. J Urol. 2012 Jul;188(1):58-62. doi: 10.1016/j.juro.2012.03.007. Epub 2012 May 12. J Urol. 2012. PMID: 22583635 Free PMC article. Clinical Trial.

7

Screening for bladder cancer: rationale, limitations, whom to target, and perspectives.

Larré S, Catto JW, Cookson MS, Messing EM, Shariat SF, Soloway MS, Svatek RS, Lotan Y, Zlotta AR, Grossman HB. Larré S, et al. Among authors: grossman hb. Eur Urol. 2013 Jun;63(6):1049-58. doi: 10.1016/j.eururo.2012.12.062. Epub 2013 Jan 8. Eur Urol. 2013. PMID: 23313034 Review.

8

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.

Habuchi T, Marberger M, Droller MJ, Hemstreet GP 3rd, Grossman HB, Schalken JA, Schmitz-Dräger BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB. Habuchi T, et al. Among authors: grossman hb. Urology. 2005 Dec;66(6 Suppl 1):64-74. doi: 10.1016/j.urology.2005.08.065. Urology. 2005. PMID: 16399416

9

Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray.

Harris LD, De La Cerda J, Tuziak T, Rosen D, Xiao L, Shen Y, Sabichi AL, Czerniak B, Grossman HB. Harris LD, et al. Among authors: grossman hb. Mol Carcinog. 2008 Sep;47(9):678-85. doi: 10.1002/mc.20420. Mol Carcinog. 2008. PMID: 18288642 Free PMC article.

10

BCAN Think Tank session 3: Prevention of bladder cancer.

Lerner SP, Grossman HB, Messing EM, Kibel AS, Stephenson A, Gee JR, O'Donnell MA, Reid RD, Kamat AM, Parnes HL, House MG. Lerner SP, et al. Among authors: grossman hb. Urol Oncol. 2010 May-Jun;28(3):338-42. doi: 10.1016/j.urolonc.2009.06.018. Urol Oncol. 2010. PMID: 20439034

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

433 results

Search Page

Filters